株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

尋常性白斑 - 市場洞察、疫学、市場予測 2028年

Vitiligo - Market Insights, Epidemiology, and Market Forecast-2028

発行 DelveInsight Business Research LLP 商品コード 703503
出版日 ページ情報 英文 143 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.78円で換算しております。
Back to Top
尋常性白斑 - 市場洞察、疫学、市場予測 2028年 Vitiligo - Market Insights, Epidemiology, and Market Forecast-2028
出版日: 2019年08月01日 ページ情報: 英文 143 Pages
概要

世界の主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の尋常性白斑の2017年の有病者数は623万4,655人、その市場規模は8億8,275万米ドルと推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)の尋常性白斑市場を調査し、市場の概要、疾病背景、国別の疫学、性別・タイプ別・年齢別の有病数/診断数の動向、アンメットニーズ、新薬および候補薬の概要、全体・国別の市場規模の推移と予測、成長要因および障壁などについてまとめています。

目次

第1章 重要洞察

第2章 尋常性白斑市場の概要

  • 市場シェア(実数値)
  • 市場シェア(予測値)

第3章 疾病背景と概要:尋常性白斑

  • イントロダクション
  • 種類
  • 原因
  • 症状
  • 病態生理
  • 遺伝学
  • 診断
    • 診断ガイドライン

第4章 疫学と患者人口

  • 主な調査結果
  • 人口と予測パラメータ
  • 主要7カ国の有病数

第5章 米国における尋常性白斑の疫学

  • 仮定と根拠
  • 有病数
  • 有病数:性別
  • 診断数
  • 診断有病数:タイプ別
  • 有病数:年齢別

第6章 欧州5カ国における尋常性白斑の疫学

  • 仮定と根拠
  • ドイツ
    • 有病数
    • 有病数:性別
    • 診断数
    • 診断有病数:タイプ別
    • 有病数:年齢別
  • フランス
  • イタリア
  • スペイン
  • 英国

第7章 日本における尋常性白斑の疫学

  • 仮定と根拠
  • 有病数
  • 有病数:性別
  • 診断数
  • 診断有病数:タイプ別
  • 有病数:年齢別

第8章 治療アルゴリズム

  • 治療ガイドライン
    • 米国皮膚科学会(AAD)
    • 欧州皮膚科学フォーラムのコンセンサス:白斑管理ガイドライン
    • 白斑日本タスクフォース(VJTF)日本皮膚科学会:治療ガイドライン

第9章 アンメットニーズ

第10章 新薬

  • INCB018424:Incyte Corporation
    • 製品説明
    • その他の開発動向
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル
  • SCENESSE:Clinuvel Pharmaceutical

第11章 その他の有望な候補薬

  • ATI-50002:Aclaris Therapeutics
    • 製品説明
    • その他の開発動向
    • 臨床開発
    • 安全性と有効性
    • 製品プロファイル
  • Apremilast:Celgene

第12章 主要7カ国の尋常性白斑市場の分析

  • 主な調査結果
  • 総市場規模
  • 市場規模:治療薬別

第13章 米国市場の見通し

  • 市場規模
    • 総市場規模
    • 市場規模:治療薬別

第14章 欧州5カ国市場の見通し

  • ドイツ
    • 総市場規模
    • 市場規模:治療薬別
  • フランス
  • イタリア
  • スペイン
  • 英国

第15章 日本市場の見通し

  • 日本
    • 総市場規模
    • 市場規模:治療薬別

第16章 市場成長要因

第17章 市場の障壁

第18章 付録

  • 調査方法

第19章 出典

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

図表

List of Tables

  • Table 1 Fitzpatrick skin types classification
  • Table 2 Levels of evidence (from Scottish Inter-Collegiate Guidelines Network)
  • Table 3 Grades of recommendation (from Scottish Inter-Collegiate Guidelines Network)
  • Table 4 Criteria for levels of evidence and grades of recommendation
  • Table 5 Total Prevalent Population of Vitiligo in 7MM (2017-2028)
  • Table 6 Prevalent Population of Vitiligo in the United States (2017-2028)
  • Table 7 Gender-Specific Prevalent Population of Vitiligo in the United States (2017-2028)
  • Table 8 Diagnosed cases of Vitiligo in the United States (2017-2028)
  • Table 9 Type-Specific Diagnosed Prevalent cases of Vitiligo in the United States (2017-2028)
  • Table 10 Age-Specific Prevalent cases of Vitiligo in the United States (2018)
  • Table 11 Prevalent Population of Vitiligo in Germany (2017-2028)
  • Table 12 Gender-Specific Prevalent Population of Vitiligo in Germany (2017-2028)
  • Table 13 Diagnosed cases of Vitiligo in Germany (2017-2028)
  • Table 14 Type-Specific Diagnosed Prevalent cases of Vitiligo in Germany (2017-2028)
  • Table 15 Age-Specific Prevalent cases of Vitiligo in Germany (2018)
  • Table 16 Prevalent Population of Vitiligo in France (2017-2028)
  • Table 17 Gender-Specific Prevalent Population of Vitiligo in France (2017-2028)
  • Table 18 Diagnosed cases of Vitiligo in the France (2017-2028)
  • Table 19 Type-Specific Diagnosed Prevalent cases of Vitiligo in France (2017-2028)
  • Table 20 Age-Specific Prevalent cases of Vitiligo in France (2018)
  • Table 21 Prevalent Population of Vitiligo in Italy (2017-2028)
  • Table 22 Gender-Specific Prevalent Population of Vitiligo in Italy (2017-2028)
  • Table 23 Diagnosed cases of Vitiligo in Italy (2017-2028)
  • Table 24 Type-Specific Diagnosed Prevalent cases of Vitiligo in Italy (2017-2028)
  • Table 25 Age-Specific Prevalent cases of Vitiligo in Italy (2018)
  • Table 26 Prevalent Population of Vitiligo in Spain (2017-2028)
  • Table 27 Gender-Specific Prevalent Population of Vitiligo in Spain (2017-2028)
  • Table 28 Diagnosed cases of Vitiligo in Spain (2017-2028)
  • Table 29 Type-Specific Diagnosed Prevalent cases of Vitiligo in Spain (2017-2028)
  • Table 30 Age-Specific Prevalent cases of Vitiligo in Spain (2018)
  • Table 31 Prevalent Population of Vitiligo in the United Kingdom (2017-2028)
  • Table 32 Gender-Specific Prevalent Population of Vitiligo in the United Kingdom (2017-2028)
  • Table 33 Diagnosed cases of Vitiligo in the UK (2017-2028)
  • Table 34 Type-Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom (2017-2028)
  • Table 35 Age-Specific Prevalent cases of Vitiligo in the UK (2018)
  • Table 36 Prevalent Population of Vitiligo in Japan (2017-2028)
  • Table 37 Gender-Specific Prevalent Population of Vitiligo in Japan (2017-2028)
  • Table 38 Diagnosed cases of Vitiligo in Japan (2017-2028)
  • Table 39 Type-Specific Diagnosed Prevalent cases of Vitiligo in Japan (2017-2028)
  • Table 40 Age-Specific Prevalent cases of Vitiligo in Japan (2018)
  • Table 41 Recommendations for the management of Vitiligo
  • Table 42 Recommendations for treatment of Vitiligo in Japan
  • Table 43 INCB018424, Clinical Trial Description, 2019
  • Table 44 SCENESSE, Clinical Trial Description, 2019
  • Table 45 ATI-50002, Clinical Trial Description, 2019
  • Table 46 Apremilast, Clinical Trial Description, 2019
  • Table 47 7 Major Market Size of Vitiligo in USD Million (2017-2028)
  • Table 48 7 Major Market Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Table 49 The US Market Vitiligo in USD Million (2017-2028)
  • Table 50 The US Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Table 51 Germany Market Vitiligo in USD Million (2017-2028)
  • Table 52 Germany Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Table 53 France Market Vitiligo in USD Million (2017-2028)
  • Table 54 France Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Table 55 Italy Market Vitiligo in USD Million (2017-2028)
  • Table 56 Italy Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Table 57 Spain Market Vitiligo in USD Million (2017-2028)
  • Table 58 Spain Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Table 59 The UK Market Vitiligo in USD Million (2017-2028)
  • Table 60 The UK Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Table 61 Japan Market Vitiligo in USD Million (2017-2028)
  • Table 62 Japan Vitiligo Market Size by Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1 Types of Vitiligo
  • Figure 2 Type of Non-segmental Vitiligo
  • Figure 3 Symptoms of Vitiligo
  • Figure 4 Cellular and Humoral immune mechanisms of Vitiligo
  • Figure 5 Pathogenesis of Vitiligo
  • Figure 6 Identification of Vitiligo susceptibility genes
  • Figure 7 Total Prevalent Population of Vitiligo in the 7 MM (2017-2028)
  • Figure 8 Prevalent Population of Vitiligo in the United States (2017-2028)
  • Figure 9 Gender-Specific Prevalent Population of Vitiligo in the United States (2017-2028)
  • Figure 10 Diagnosed cases of Vitiligo in the United States (2017-2028)
  • Figure 11 Type-Specific Diagnosed Prevalent cases of Vitiligo in the United States (2017-2028)
  • Figure 12 Age-Specific Prevalent cases of Vitiligo in the United States (2018)
  • Figure 13 Prevalent Population of Vitiligo in Germany (2017-2028)
  • Figure 14 Gender-Specific Prevalent Population of Vitiligo in Germany (2017-2028)
  • Figure 15 Diagnosed cases of Vitiligo in Germany (2017-2028)
  • Figure 16 Type-Specific Diagnosed Prevalent cases of Vitiligo in Germany (2017-2028)
  • Figure 17 Age-Specific Prevalent cases of Vitiligo in Germany (2018)
  • Figure 18 Prevalent Population of Vitiligo in France (2017-2028)
  • Figure 19 Gender-Specific Prevalent Population of Vitiligo in France (2017-2028)
  • Figure 20 Diagnosed cases of Vitiligo in France (2017-2028)
  • Figure 21 Type-Specific Diagnosed Prevalent cases of Vitiligo in France (2017-2028)
  • Figure 22 Age-Specific Prevalent cases of Vitiligo in France (2018)
  • Figure 23 Prevalent Population of Vitiligo in Italy (2017-2028)
  • Figure 24 Gender-Specific Prevalent Population of Vitiligo in Italy (2017-2028)
  • Figure 25 Diagnosed cases of Vitiligo in Italy (2017-2028)
  • Figure 26 Type-Specific Diagnosed Prevalent cases of Vitiligo in Italy (2017-2028)
  • Figure 27 Age-Specific Prevalent cases of Vitiligo in Italy (2018)
  • Figure 28 Prevalent Population of Vitiligo in Spain (2017-2028)
  • Figure 29 Gender-Specific Prevalent Population of Vitiligo in Spain (2017-2028)
  • Figure 30 Diagnosed cases of Vitiligo in Spain (2017-2028)
  • Figure 31 Type-Specific Diagnosed Prevalent cases of Vitiligo in Spain (2017-2028)
  • Figure 32 Age-Specific Prevalent cases of Vitiligo in Spain (2018)
  • Figure 33 Prevalent Population of Vitiligo in the United Kingdom (2017-2028)
  • Figure 34 Gender-Specific Prevalent Population of Vitiligo in the United Kingdom (2017-2028)
  • Figure 35 Diagnosed cases of Vitiligo in the UK (2017-2028)
  • Figure 36 Type-Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom (2017-2028)
  • Figure 37 Age-Specific Prevalent cases of Vitiligo in the UK (2018)
  • Figure 38 Prevalent Population of Vitiligo in Japan (2017-2028)
  • Figure 39 Gender-Specific Prevalent Population of Vitiligo in Japan (2017-2028)
  • Figure 40 Diagnosed cases of Vitiligo in Japan (2017-2028)
  • Figure 41 Type-Specific Diagnosed Prevalent cases of Vitiligo in Japan (2017-2028)
  • Figure 42 Age-Specific Prevalent cases of Vitiligo in Japan (2018)
  • Figure 43 Treatment algorithm for Vitiligo
  • Figure 44 Treatment algorithm for the segmental variant of Vitiligo
  • Figure 45 Treatment algorithm for the segmental variant of Vitiligo
  • Figure 46 Treatment algorithm for Vitiligo
  • Figure 47 Proposed algorithm for the treatment of Vitiligo in Japan
  • Figure 48 Unmet Needs for Vitiligo
  • Figure 49 7 Major Market Size of Vitiligo in USD Million (2017-2028)
  • Figure 50 7 Major Market Size of Vitiligo by Therapies in USD Million (2017-2028)
  • Figure 51 Market Size of Vitiligo in the United States, USD Millions (2017-2028)
  • Figure 52 The U.S. Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Figure 53 Market Size of Vitiligo in the Germany, USD Millions (2017-2028)
  • Figure 54 Germany Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Figure 55 Market Size of Vitiligo in France, USD Millions (2017-2028)
  • Figure 56 France Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Figure 57 Market Size of Vitiligo in Italy, USD Millions (2017-2028)
  • Figure 58 Italy Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Figure 59 Market Size of Vitiligo in Spain, USD Millions (2017-2028)
  • Figure 60 Spain Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Figure 61 Market Size of Vitiligo in the UK, USD Millions (2017-2028)
  • Figure 62 The UK Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Figure 63 Market Size of Vitiligo in Japan, USD Millions (2017-2028)
  • Figure 64 Japan Vitiligo Market Size by Therapies in USD Million (2017-2028)
  • Figure 65 Market Drivers of Vitiligo
  • Figure 66 Market Barriers of Vitiligo
目次
Product Code: DIMI0067

DelveInsight's 'Vitiligo - Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Vitiligo in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Vitiligo from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Vitiligo - Disease Understanding and Treatment Algorithm

The DelveInsight Vitiligo market report gives a thorough understanding of the Vitiligo by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Vitiligo in the US, Europe, and Japan.

Vitiligo

The Vitiligo epidemiology division provide insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Prevalence of Vitiligo in 7MM, Total Diagnosed Prevalence of Vitiligo in 7MM, Gender-specific Prevalence of Vitiligo in 7MM, Age-specific Diagnosed Prevalence of Vitiligo in 7MM, and Type-specific Diagnosed Prevalence of Vitiligo in 7MM) scenario of Vitiligo in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of prevalent population of Vitiligo was found to be 6,234,655 in 7MM in the year 2017.

Vitiligo Drug Chapters

This segment of the Vitiligo report encloses the detailed analysis of late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, the therapeutic market Size of Vitiligo in the United States is mainly accounted for by the off-label use of Corticosteroids and Calcineurin inhibitors, both as monotherapy as well as combination therapies. These therapies are also combined with Phototherapy (phototherapy as a monotherapy is not included in the market size estimation) for treating Vitiligo and, the market size of Vitiligo in the United States is inclusive of the revenue generated by these combination therapies [i.e., Corticosteroids + Calcineurin inhibitors and Corticosteroids + Calcineurin inhibitors + Phototherapy].

Topical Corticosteroids and calcineurin inhibitors constitute the first line of treatment for Vitiligo. Both of these therapies act by diminishing the cellular immune response.

However, the most significant combinational therapy, that contributes the most toward the market size, is a combination of Corticosteroids, calcineurin inhibitors, and Phototherapy. Although the patient share opting for this combination, is quite nominal, however, the higher cost of treatment is the main reason behind a large amount of market revenue generated by the combined usage of these therapies.

The above-mentioned off-label therapies currently hold the market of Vitiligo in the United States. However, the dynamics of Vitiligo market is anticipated to change during the forecasted period. Companies have shifted their focus on the development of targeted treatment for Vitiligo, (mostly JAK inhibitors) and owing to the expected launch of emerging therapies during the forecasted period of (2019-2028), the market size is expected to increase in subsequent years.

Vitiligo Market Outlook

The Vitiligo market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Vitiligo in 7MM was found to be USD 882.75 million in 2017 and is expected to increase at a CAGR of XX% from 2017-2028.

Vitiligo Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Vitiligo Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Vitiligo Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Vitiligo Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Vitiligo Infections market
  • Organize sales and marketing efforts by identifying the best opportunities for Vitiligo market
  • To understand the future market competition in the Vitiligo market.

Table of Contents

1. Key Insights

2. Vitiligo Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Vitiligo in 2017
  • 2.2. Market Share (%) Distribution of Vitiligo in 2028

3. Disease Background and Overview: Vitiligo

  • 3.1. Introduction
  • 3.2. Types of Vitiligo
  • 3.3. Causes of Vitiligo
  • 3.4. Symptoms of Vitiligo
  • 3.5. Pathophysiology
  • 3.6. Genetics of Vitiligo
  • 3.7. Diagnosis
    • 3.7.1. Diagnostic Guidelines

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. Prevalent Population of Vitiligo in 7MM

5. United States-Epidemiology of Vitiligo

  • 5.1. Assumptions and Rationale
  • 5.2. Prevalent Population of Vitiligo in the United States
  • 5.3. Gender-Specific Prevalent Population of Vitiligo in the United States
  • 5.4. Diagnosed Cases of Vitiligo in the United States
  • 5.5. Type-Specific Diagnosed Prevalent cases of Vitiligo in the United States
  • 5.6. Age-Specific Prevalent cases of Vitiligo in the United States

6. EU-5 Epidemiology of Vitiligo

  • 6.1. Assumptions and Rationale
  • 6.2. Germany
    • 6.2.1. Prevalent Population of Vitiligo in Germany
    • 6.2.2. Gender-Specific Prevalent Population of Vitiligo in Germany
    • 6.2.3. Diagnosed Cases of Vitiligo in Germany
    • 6.2.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in Germany
    • 6.2.5. Age-Specific Prevalent cases of Vitiligo in Germany
  • 6.3. France
    • 6.3.1. Prevalent Population of Vitiligo in France
    • 6.3.2. Gender-Specific Prevalent Population of Vitiligo in France
    • 6.3.3. Diagnosed Cases of Vitiligo in France
    • 6.3.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in France
    • 6.3.5. Age-Specific Prevalent cases of Vitiligo in France
  • 6.4. Italy
    • 6.4.1. Prevalent Population of Vitiligo in Italy
    • 6.4.2. Gender-Specific Prevalent Population of Vitiligo in Italy
    • 6.4.3. Diagnosed Cases of Vitiligo in Italy
    • 6.4.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in Italy
    • 6.4.5. Age-Specific Prevalent cases of Vitiligo in Italy
  • 6.5. Spain
    • 6.5.1. Prevalent Population of Vitiligo in Spain
    • 6.5.2. Gender-Specific Prevalent Population of Vitiligo in Spain
    • 6.5.3. Diagnosed Cases of Vitiligo in Spain
    • 6.5.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in Spain
    • 6.5.5. Age-Specific Prevalent cases of Vitiligo in Spain
  • 6.6. United Kingdom
    • 6.6.1. Prevalent Population of Vitiligo in the United Kingdom
    • 6.6.2. Gender-Specific Prevalent Population of Vitiligo in the United Kingdom
    • 6.6.3. Diagnosed Cases of Vitiligo in the UK
    • 6.6.4. Type-Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom
    • 6.6.5. Age-Specific Prevalent cases of Vitiligo in the UK

7. Japan-Epidemiology of Vitiligo

  • 7.1. Assumptions and Rationale
  • 7.2. Prevalent Population of Vitiligo in Japan
  • 7.3. Gender-Specific Prevalent Population of Vitiligo in Japan
  • 7.4. Diagnosed Cases of Vitiligo in Japan
  • 7.5. Type-Specific Diagnosed Prevalent cases of Vitiligo in Japan
  • 7.6. Age-Specific Prevalent cases of Vitiligo in Japan

8. Treatment Algorithm

  • 8.1. Treatment Guidelines
    • 8.1.1. American Association of Dermatology (AAD)
    • 8.1.2. The European Dermatology Forum Consensus: Management guidelines for Vitiligo
    • 8.1.3. Vitiligo Japanese Task Force (VJTF); Japanese Dermatological Association: Treatment Guidelines

9. Unmet Needs

10. Emerging Therapies

  • 10.1. INCB018424: Incyte Corporation
    • 10.1.1. Product Description
    • 10.1.2. Other development activities
    • 10.1.3. Clinical Development
    • 10.1.4. Safety and Efficacy
    • 10.1.5. Product Profile
  • 10.2. SCENESSE (afamelanotide): Clinuvel Pharmaceutical
    • 10.2.1. Product Description
    • 10.2.2. Clinical Development
    • 10.2.3. Safety and Efficacy
    • 10.2.4. Product Profile

11. Other Promising Candidates

  • 11.1. ATI-50002: Aclaris Therapeutics
    • 11.1.1. Product Description
    • 11.1.2. Other Development Activities
    • 11.1.3. Clinical Development
    • 11.1.4. Safety and Efficacy
    • 11.1.5. Product Profile
  • 11.2. Apremilast: Celgene
    • 11.2.1. Product Description
    • 11.2.2. Clinical Development
    • 11.2.3. Product Profile

12. Vitiligo: 7 Major Market Analysis

  • 12.1. Key Findings
  • 12.2. Total Market Size of Vitiligo in 7MM
  • 12.3. 7 MM Size of Vitiligo by Therapies

13. The United States: Market Outlook

  • 13.1. United States Market Size
    • 13.1.1. Total Market size of Vitiligo
    • 13.1.2. Vitiligo Market Size by Therapies

14. EU-5 Countries: Market Outlook

  • 14.1. Germany Market Size
    • 14.1.1. Total Market size of Vitiligo
    • 14.1.2. Vitiligo Market Size by Therapies
  • 14.2. France Market Size
    • 14.2.1. Total Market size of Vitiligo
    • 14.2.2. Vitiligo Market Size by Therapies
  • 14.3. Italy Market Size
    • 14.3.1. Total Market size of Vitiligo
    • 14.3.2. Vitiligo Market Size by Therapies
  • 14.4. Spain Market Size
    • 14.4.1. Total Market size of Vitiligo
    • 14.4.2. Vitiligo Market Size Therapies
  • 14.5. The United Kingdom Market Size
    • 14.5.1. Total Market size of Vitiligo
    • 14.5.2. Vitiligo Market Size by Therapies

15. Japan: Market Outlook

  • 15.1. Japan: Market Size
    • 15.1.1. Total Market size of Vitiligo
    • 15.1.2. Vitiligo Market Size by Therapies

16. Market Drivers

17. Market Barriers

18. Appendix

  • 18.1. Report Methodology

19. Sources Used

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Back to Top